Replimune Group Stock Forecast, Price & News

Replimune Group's stock was trading at $11.93 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, REPL shares have increased by 334.5% and is now trading at $51.83.
View which stocks have been most impacted by COVID-19.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Replimune Group.

Wall Street analysts have given Replimune Group a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Replimune Group wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Replimune Group is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for Replimune Group.

Replimune Group, Inc. (NASDAQ:REPL) released its earnings results on Thursday, November, 5th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.03.
View Replimune Group's earnings history.

9 Wall Street analysts have issued 12 month target prices for Replimune Group's stock. Their forecasts range from $44.00 to $67.00. On average, they expect Replimune Group's share price to reach $54.25 in the next twelve months. This suggests a possible upside of 4.7% from the stock's current price.
View analysts' price targets for Replimune Group.

Replimune Group saw a increase in short interest in October. As of October 30th, there was short interest totaling 1,020,000 shares, an increase of 29.8% from the October 15th total of 785,700 shares. Based on an average trading volume of 611,600 shares, the short-interest ratio is presently 1.7 days. Currently, 4.0% of the company's shares are sold short.
View Replimune Group's Short Interest.

Some companies that are related to Replimune Group include Neurocrine Biosciences (NBIX), CRISPR Therapeutics (CRSP), Novavax (NVAX), Denali Therapeutics (DNLI), Acceleron Pharma (XLRN), Adaptive Biotechnologies (ADPT), Kodiak Sciences (KOD), Iovance Biotherapeutics (IOVA), Halozyme Therapeutics (HALO), Twist Bioscience (TWST), Fate Therapeutics (FATE), Immunovant (IMVT), Relay Therapeutics (RLAY), China Biologic Products (CBPO) and Allogene Therapeutics (ALLO).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), (BTUUQ) (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU), Pfizer (PFE), SCYNEXIS (SCYX), Exelixis (EXEL) and Fulcrum Therapeutics (FULC).

(REPL) raised $100 million in an initial public offering on Friday, July 20th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

Replimune Group trades on the NASDAQ under the ticker symbol "REPL."

Replimune Group's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.75%), Victory Capital Management Inc. (2.96%), Point72 Asset Management L.P. (2.15%), Emerald Advisers LLC (2.21%), Emerald Mutual Fund Advisers Trust (2.05%) and Corriente Advisors LLC (1.27%). Company insiders that own Replimune Group stock include Colin Love, Fund Iv LP Omega, Jason P Rhodes, Pamela Esposito, Philip Astley-Sparke and Robert Coffin.
View institutional ownership trends for Replimune Group.

REPL stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, and Wells Fargo & Company MN. Company insiders that have sold Replimune Group company stock in the last year include Colin Love, Pamela Esposito, and Robert Coffin.
View insider buying and selling activity for Replimune Group.

REPL stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., BlackRock Inc., Charles Schwab Investment Management Inc., Caas Capital Management LP, Victory Capital Management Inc., Letko Brosseau & Associates Inc., Emerald Advisers LLC, and JPMorgan Chase & Co.. Company insiders that have bought Replimune Group stock in the last two years include Fund Iv LP Omega, and Jason P Rhodes.
View insider buying and selling activity for Replimune Group.

Shares of REPL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of REPL stock can currently be purchased for approximately $51.83.

Replimune Group has a market capitalization of $2.38 billion. The company earns $-52,630,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis. Replimune Group employs 122 workers across the globe.

The official website for Replimune Group is www.replimune.com.

Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The company can be reached via phone at 781-222-9600 or via email at [email protected]